Review



spotbot ii microarray printer  (Arrayit Corporation)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Arrayit Corporation spotbot ii microarray printer
    Comparison of USA vs. Colombia MIS-C patient samples by GCFP <t>microarray.</t> (A) Heat map of A2 serum samples comparing USA to Colombia samples. The USA patient population has a more robust signature. (B) Heat of A2 saliva samples comparing USA to Colombia samples, USA has a more robust signature.
    Spotbot Ii Microarray Printer, supplied by Arrayit Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/spotbot ii microarray printer/product/Arrayit Corporation
    Average 90 stars, based on 1 article reviews
    spotbot ii microarray printer - by Bioz Stars, 2026-03
    90/100 stars

    Images

    1) Product Images from "Development of a biomarker signature using grating-coupled fluorescence plasmonic microarray for diagnosis of MIS-C"

    Article Title: Development of a biomarker signature using grating-coupled fluorescence plasmonic microarray for diagnosis of MIS-C

    Journal: Frontiers in Bioengineering and Biotechnology

    doi: 10.3389/fbioe.2023.1066391

    Comparison of USA vs. Colombia MIS-C patient samples by GCFP microarray. (A) Heat map of A2 serum samples comparing USA to Colombia samples. The USA patient population has a more robust signature. (B) Heat of A2 saliva samples comparing USA to Colombia samples, USA has a more robust signature.
    Figure Legend Snippet: Comparison of USA vs. Colombia MIS-C patient samples by GCFP microarray. (A) Heat map of A2 serum samples comparing USA to Colombia samples. The USA patient population has a more robust signature. (B) Heat of A2 saliva samples comparing USA to Colombia samples, USA has a more robust signature.

    Techniques Used: Comparison, Microarray

    Serum from Cohorts and individual patient comparison of GCFP microarray assay to MIA. To compare a traditional MIA with the GCFP microarray, 11 analytes were included in both assays. (A) A heat map was generated by log transforming GCFP detection ratios and using the mean of each analyte detection ratio for each cohort. Of the 11 analytes, 5 were below the detection limit of the GCFP first generation biosensor chip. (B) A heat map generated by log transforming GCFP detection ratios from individual serum samples from cohort A1. (C) A heat map generated by log transforming GCFP detection ratios from individual serum samples from cohort A2. (D) A heat map generated by log transforming GCFP detection ratios from individual serum samples from cohort B1. (E) A heat map generated by log transforming GCFP detection ratios from individual serum samples from cohort B2. (F) A heat map generated by log transforming GCFP detection ratios from individual serum samples from cohort B3. 16 of the 44 shared serum samples had similar biomarker signatures, while IL-4, IL-6 and CCL20 were not consistently detected on the GCFP chip.
    Figure Legend Snippet: Serum from Cohorts and individual patient comparison of GCFP microarray assay to MIA. To compare a traditional MIA with the GCFP microarray, 11 analytes were included in both assays. (A) A heat map was generated by log transforming GCFP detection ratios and using the mean of each analyte detection ratio for each cohort. Of the 11 analytes, 5 were below the detection limit of the GCFP first generation biosensor chip. (B) A heat map generated by log transforming GCFP detection ratios from individual serum samples from cohort A1. (C) A heat map generated by log transforming GCFP detection ratios from individual serum samples from cohort A2. (D) A heat map generated by log transforming GCFP detection ratios from individual serum samples from cohort B1. (E) A heat map generated by log transforming GCFP detection ratios from individual serum samples from cohort B2. (F) A heat map generated by log transforming GCFP detection ratios from individual serum samples from cohort B3. 16 of the 44 shared serum samples had similar biomarker signatures, while IL-4, IL-6 and CCL20 were not consistently detected on the GCFP chip.

    Techniques Used: Comparison, Microarray, Generated, Biomarker Discovery



    Similar Products

    spotbot ii microarray printer  (Arrayit Corporation)
    90
    Arrayit Corporation spotbot ii microarray printer
    Comparison of USA vs. Colombia MIS-C patient samples by GCFP <t>microarray.</t> (A) Heat map of A2 serum samples comparing USA to Colombia samples. The USA patient population has a more robust signature. (B) Heat of A2 saliva samples comparing USA to Colombia samples, USA has a more robust signature.
    Spotbot Ii Microarray Printer, supplied by Arrayit Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/spotbot ii microarray printer/product/Arrayit Corporation
    Average 90 stars, based on 1 article reviews
    spotbot ii microarray printer - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    microarray printer spotbot ii  (Arrayit Corporation)
    90
    Arrayit Corporation microarray printer spotbot ii
    Comparison of USA vs. Colombia MIS-C patient samples by GCFP <t>microarray.</t> (A) Heat map of A2 serum samples comparing USA to Colombia samples. The USA patient population has a more robust signature. (B) Heat of A2 saliva samples comparing USA to Colombia samples, USA has a more robust signature.
    Microarray Printer Spotbot Ii, supplied by Arrayit Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/microarray printer spotbot ii/product/Arrayit Corporation
    Average 90 stars, based on 1 article reviews
    microarray printer spotbot ii - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Comparison of USA vs. Colombia MIS-C patient samples by GCFP microarray. (A) Heat map of A2 serum samples comparing USA to Colombia samples. The USA patient population has a more robust signature. (B) Heat of A2 saliva samples comparing USA to Colombia samples, USA has a more robust signature.

    Journal: Frontiers in Bioengineering and Biotechnology

    Article Title: Development of a biomarker signature using grating-coupled fluorescence plasmonic microarray for diagnosis of MIS-C

    doi: 10.3389/fbioe.2023.1066391

    Figure Lengend Snippet: Comparison of USA vs. Colombia MIS-C patient samples by GCFP microarray. (A) Heat map of A2 serum samples comparing USA to Colombia samples. The USA patient population has a more robust signature. (B) Heat of A2 saliva samples comparing USA to Colombia samples, USA has a more robust signature.

    Article Snippet: Capture antibodies were diluted to 250 μg/mL with PBS ( ) and printed on the GCFP chips using a 0.35 mm diameter microarray pin and a SpotBot II microarray printer (ArrayIt, CA, United States) or an XactII microarray printer (LabNEXT, NJ, United States).

    Techniques: Comparison, Microarray

    Serum from Cohorts and individual patient comparison of GCFP microarray assay to MIA. To compare a traditional MIA with the GCFP microarray, 11 analytes were included in both assays. (A) A heat map was generated by log transforming GCFP detection ratios and using the mean of each analyte detection ratio for each cohort. Of the 11 analytes, 5 were below the detection limit of the GCFP first generation biosensor chip. (B) A heat map generated by log transforming GCFP detection ratios from individual serum samples from cohort A1. (C) A heat map generated by log transforming GCFP detection ratios from individual serum samples from cohort A2. (D) A heat map generated by log transforming GCFP detection ratios from individual serum samples from cohort B1. (E) A heat map generated by log transforming GCFP detection ratios from individual serum samples from cohort B2. (F) A heat map generated by log transforming GCFP detection ratios from individual serum samples from cohort B3. 16 of the 44 shared serum samples had similar biomarker signatures, while IL-4, IL-6 and CCL20 were not consistently detected on the GCFP chip.

    Journal: Frontiers in Bioengineering and Biotechnology

    Article Title: Development of a biomarker signature using grating-coupled fluorescence plasmonic microarray for diagnosis of MIS-C

    doi: 10.3389/fbioe.2023.1066391

    Figure Lengend Snippet: Serum from Cohorts and individual patient comparison of GCFP microarray assay to MIA. To compare a traditional MIA with the GCFP microarray, 11 analytes were included in both assays. (A) A heat map was generated by log transforming GCFP detection ratios and using the mean of each analyte detection ratio for each cohort. Of the 11 analytes, 5 were below the detection limit of the GCFP first generation biosensor chip. (B) A heat map generated by log transforming GCFP detection ratios from individual serum samples from cohort A1. (C) A heat map generated by log transforming GCFP detection ratios from individual serum samples from cohort A2. (D) A heat map generated by log transforming GCFP detection ratios from individual serum samples from cohort B1. (E) A heat map generated by log transforming GCFP detection ratios from individual serum samples from cohort B2. (F) A heat map generated by log transforming GCFP detection ratios from individual serum samples from cohort B3. 16 of the 44 shared serum samples had similar biomarker signatures, while IL-4, IL-6 and CCL20 were not consistently detected on the GCFP chip.

    Article Snippet: Capture antibodies were diluted to 250 μg/mL with PBS ( ) and printed on the GCFP chips using a 0.35 mm diameter microarray pin and a SpotBot II microarray printer (ArrayIt, CA, United States) or an XactII microarray printer (LabNEXT, NJ, United States).

    Techniques: Comparison, Microarray, Generated, Biomarker Discovery